Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Vifor Pharma Teams with Evotec to Form Joint Venture

Swiss company Vifor Pharma and Germany’s Evotec AG launched a joint venture to focus on the discovery and development of new therapies for kidney diseases.

Read More »

Daiichi Sankyo and Seattle Genetics Headed to Court

Daiichi Sankyo is taking Seattle Genetics to court over the technology the two companies used to develop antibody-drug conjugates (ADCs) during a partnership that spanned seven years.

Read More »

Biogen resurrects Alzheimer’s drug; shares jump 27%

Biogen Inc. revived plans to seek U.S. approval for the experimental Alzheimer’s treatment aducanumab, surprising investors.

Read More »

Novo Nordisk, bluebird bio Enter Gene Therapy Pact

Cambridge, Mass.-based bluebird bio and Bagsvaerd, Denmark-based Novo Nordisk agreed to develop next-generation genome editing therapies for genetic diseases, including hemophilia.

Read More »

W2O Acquires Arcus Medica to Accelerate and Deepen Scientific and Medical Communications Offering

W2O – a leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector – acquired Arcus Medica, a recognized leader in medical and scientific communications.

Read More »

4D Pharma and Merck Team to Develop Microbiome-based Vaccines

Leeds, UK-based 4D Pharma and Merck/MSD are developing Live Biotherapeutics vaccines, a new class of medicines.

Read More »

uBiome to Close Doors One Month After Bankruptcy Filing

Less than one month after filing for bankruptcy, uBiome is shutting the Bay Area microbiome company’s doors and selling off assets.

Read More »

Sanofi to pay Lexicon for terminated partnership

Lexicon Pharmaceuticals Inc. said France’s Sanofi SA will pay the Texas-based drugmaker $260 million for the termination of their partnership to develop the diabetes drug Zynquista.

Read More »

Cognoa and Eversana announce partnership to advance commercialization standard for prescription digital medicines

Cognoa and Eversana announced a partnership to advance the industry standard by which digital medicines will be ordered, dispensed, and covered by insurance.

Read More »

Boston’s Vida Ventures Snags $600 Million for New Life Science Fund

Boston-based venture capital firm Vida Ventures raised $600 million for the new, oversubscribed life science fund Vida Ventures II.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom